buspirone has been researched along with Irritable Bowel Syndrome in 2 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Buspirone was eventually introduced." | 5.62 | Buspirone in the management of refractory irritable bowel syndrome: A case report. ( Al-Baz, N; Alabdulla, M; Haddad, PM; Karim, MA; Reagu, SM, 2021) |
| "Buspirone was eventually introduced." | 1.62 | Buspirone in the management of refractory irritable bowel syndrome: A case report. ( Al-Baz, N; Alabdulla, M; Haddad, PM; Karim, MA; Reagu, SM, 2021) |
| "Buspirone (30 mg) was used to stimulate prolactin release in 40 patients with IBS and in 40 healthy controls." | 1.35 | Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model. ( Chua, AS; Clarke, G; Dinan, TG; Keeling, PW; O'Mahony, S; Quigley, EM; Shanahan, F, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karim, MA | 1 |
| Al-Baz, N | 1 |
| Haddad, PM | 1 |
| Reagu, SM | 1 |
| Alabdulla, M | 1 |
| O'Mahony, S | 1 |
| Chua, AS | 1 |
| Quigley, EM | 1 |
| Clarke, G | 1 |
| Shanahan, F | 1 |
| Keeling, PW | 1 |
| Dinan, TG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Kynurenine Pathway Metabolites as Novel Translational Biological Markers of Irritable Bowel Syndrome: Relationship to Gastrointestinal Function, Cognition and Co-morbid Depression[NCT01304355] | 85 participants (Anticipated) | Observational | 2011-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for buspirone and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Buspirone in the management of refractory irritable bowel syndrome: A case report.
Topics: Abdominal Pain; Adult; Buspirone; Humans; Irritable Bowel Syndrome; Male; Quality of Life; Serotonin | 2021 |
Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model.
Topics: Adolescent; Adult; Animals; Animals, Newborn; Buspirone; Disease Models, Animal; Female; Humans; Irr | 2008 |